Top

Published in:

01-12-2018 | Case Report

Management of a Mycobacterium immunogenum infection of a peritoneal dialysis catheter site

Authors: Abhishek Shenoy, Walid El-Nahal, McCall Walker, Tushar Chopra, Gregory Townsend, Scott Heysell, Joshua Eby

Published in: Infection | Issue 6/2018

Abstract

Mycobacterium immunogenum is a member of the rapidly growing non-tuberculous mycobacteria and is a relatively new species identified within this group. An 81-year-old immune-competent male was diagnosed with M. immunogenum infection of his peritoneal dialysis catheter exit site and surrounding soft tissue. To our knowledge, this is the first reported case of M. immunogenum infection of a peritoneal catheter. Treatment included catheter removal, local surgical debridement, and combination antimicrobial therapy. Herein, we review literature describing antibiotic management of M. immunogenum, an organism for which optimal therapy is not defined.

Wilson RW, Steingrube VA, Böttger EC, et al. Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. Int J Syst Evol Microbiol. 2001;51:1751–64. https://doi.org/10.1099/00207713-51-5-1751.CrossRefPubMed

Adékambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol. 2004;42:5493–501. https://doi.org/10.1128/JCM.42.12.5493-5501.2004.CrossRefPubMedPubMedCentral

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. https://doi.org/10.1164/rccm.200604-571ST.CrossRefPubMed

Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis. 2007;20:198. https://doi.org/10.1097/QCO.0b013e328055d9a2.CrossRefPubMed

Rodriguez-Coste MA, Chirca I, Steed LL, Salgado CD. Epidemiology of rapidly growing mycobacteria bloodstream infections. Am J Med Sci. 2016;351:253–8. https://doi.org/10.1016/j.amjms.2015.12.012.CrossRefPubMed

Brown-Elliott BA, Hanson K, Vasireddy S, et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. J Clin Microbiol. 2015;53:875–8. https://doi.org/10.1128/JCM.02936-14.CrossRefPubMedPubMedCentral

Brown-Elliott BA, Wallace RJ. In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria. J Clin Microbiol. 2017;55:1747–54. https://doi.org/10.1128/JCM.00274-17.CrossRefPubMedPubMedCentral

Tse K-C, Lui S-L, Cheng VC-C, Yip TP-S, Lo WK. A cluster of rapidly growing mycobacterial peritoneal dialysis catheter exit-site infections. Am J Kidney Dis. 2007;50:e1–5. https://doi.org/10.1053/j.ajkd.2007.04.017.CrossRefPubMed

Mooren VHJF, Bleeker MWP, van Ingen J, Hermans MHA, Wever PC. Disseminated Mycobacterium abscessus infection in a peritoneal dialysis patient. IDCases. 2017;9:6–7. https://doi.org/10.1016/j.idcr.2017.05.001.CrossRefPubMedPubMedCentral

10.

Rhodes G, Fluri A, Ruefenacht A, Gerber M, Pickup R. Implementation of a quantitative real-time PCR assay for the detection of Mycobacterium immunogenum in metalworking fluids. J Occup Environ Hyg. 2011;8:478–83. https://doi.org/10.1080/15459624.2011.590737.CrossRefPubMed

11.

Ahmed RA, Shandro C, Tyrrell GJ, Sharma MK, Miedzinski LJ. Safety of injecting insulin through clothes: a case of Mycobacterium immunogenum cutaneous infection and review of the literature. Clin Diabetes. 2013;31:76–8. https://doi.org/10.2337/diaclin.31.2.76.CrossRef

12.

Sampaio JLM, Junior DN, de Freitas D, et al. An outbreak of keratitis caused by Mycobacterium immunogenum. J Clin Microbiol. 2006;44:3201–7. https://doi.org/10.1128/JCM.00656-06.CrossRefPubMedPubMedCentral

13.

Greninger AL, Langelier C, Cunningham G, et al. Two rapidly growing mycobacterial species isolated from a brain abscess: first whole-genome sequences of Mycobacterium immunogenum and Mycobacterium llatzerense. J Clin Microbiol. 2015;53:2374–7. https://doi.org/10.1128/JCM.00402-15.CrossRefPubMedPubMedCentral

14.

Biggs HM, Chudgar SM, Pfeiffer CD, Rice KR, Zaas AK, Wolfe CR. Disseminated Mycobacterium immunogenum infection presenting with septic shock and skin lesions in a renal transplant recipient. Transpl Infect Dis. 2012;14:415–21. https://doi.org/10.1111/j.1399-3062.2012.00730.x.CrossRefPubMed

15.

Del-Castillo M, Palmero D, Lopez B, et al. Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerg Infect Dis. 2009;15:357–9.CrossRefPubMed

16.

Garcia-Zamora E, Sanz-Robles H, Elosua-Gonzalez M, Rodriguez-Vasquez X, Lopez-Estebaranz JL. Cutaneous infection due to Mycobacterium immunogenum: an European case report and review of the literature. Dermatol Online J. 2017;23:1–4.

17.

Mitchell CB, Isenstein A, Burkhart CN, Groben P, Morrell DS. Infection with Mycobacterium immunogenum following a tattoo. J Am Acad Dermatol. 2011;64:e70–1. https://doi.org/10.1016/j.jaad.2009.12.037.CrossRefPubMed

18.

Loots MAM, de Jong MD, van Soolingen D, Wetsteyn JCFM, Faber WR. Chronic leg ulcer caused by Mycobacterium immunogenum. J Travel Med. 2005;12:347–9.CrossRefPubMed

19.

Shedd AD, Edhegard KD, Lugo-Somolinos A. Mycobacterium immunogenum skin infections: two different presentations. Int J Dermatol. 2010;49:941–4. https://doi.org/10.1111/j.1365-4632.2009.04363.x.CrossRefPubMed

20.

Tam PYI, Kline S, Ward G, Ferrieri P. Non-tuberculous mycobacterial infection in hospitalized children: a case series. Epidemiol Infect. 2015;143:3173–81. https://doi.org/10.1017/S0950268815000333.CrossRef

21.

Guo Q, Chu H, Ye M, et al. The clarithromycin susceptibility genotype affects the treatment outcome of patients with mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2018;62:e02360–17. https://doi.org/10.1128/AAC.02360-17.CrossRefPubMedPubMedCentral

22.

Koh W-J, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183:405–10. https://doi.org/10.1164/rccm.201003-0395OC.CrossRefPubMed

23.

Hanson KE, Slechta ES, Muir H, Barker AP. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? J Clin Microbiol. 2014;52:1705–7. https://doi.org/10.1128/JCM.03464-13.CrossRefPubMedPubMedCentral

24.

Choi G-E, Shin SJ, Won C-J, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186:917–25. https://doi.org/10.1164/rccm.201111-2005OC.CrossRefPubMed

25.

Amaral EP, Conceição EL, Costa DL, et al. N-Acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC Microbiol. 2016;16:251. https://doi.org/10.1186/s12866-016-0872-7.CrossRefPubMedPubMedCentral

26.

Kranzer K, Elamin WF, Cox H, Seddon JA, Ford N, Drobniewski F. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax. 2015;70:1070–7. https://doi.org/10.1136/thoraxjnl-2015-207245.CrossRefPubMed

27.

Cowman S, Burns K, Benson S, Wilson R, Loebinger MR. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect. 2016;72:324–31. https://doi.org/10.1016/j.jinf.2015.12.007.CrossRefPubMed

28.

Hatakeyama S, Ohama Y, Okazaki M, Nukui Y, Moriya K. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis. 2017;17:197. https://doi.org/10.1186/s12879-017-2298-8.CrossRefPubMedPubMedCentral

29.

Ferro BE, Srivastava S, Deshpande D, et al. Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother. 2016;60:2895–900. https://doi.org/10.1128/AAC.03112-15.CrossRefPubMedPubMedCentral

30.

Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152:800–9. https://doi.org/10.1016/j.chest.2017.04.175.CrossRefPubMed

31.

Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother. 2016;60:1097–105. https://doi.org/10.1128/AAC.02615-15.CrossRefPubMedPubMedCentral

32.

Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC. Risk of sensorineural hearing loss with macrolide antibiotics: a nested case-control study. Laryngoscope. 2017;127:229–32. https://doi.org/10.1002/lary.26190.CrossRefPubMed

33.

Mick P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol. 2007;36:257–63.CrossRefPubMed

34.

Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol. 2000;109:435–7. https://doi.org/10.1177/000348940010900416.CrossRefPubMed

35.

Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015;45:1177–9. https://doi.org/10.1183/09031936.00169114.CrossRefPubMedPubMedCentral

36.

Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47:543–60. https://doi.org/10.1345/aph.1R604.CrossRefPubMed

Title: Management of a Mycobacterium immunogenum infection of a peritoneal dialysis catheter site
Authors: Abhishek Shenoy
Walid El-Nahal
McCall Walker
Tushar Chopra
Gregory Townsend
Scott Heysell
Joshua Eby
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 6/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-018-1199-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Cutaneous mucormycosis

Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection

Clinical and microbiological characteristics of adult invasive Haemophilus influenzae infections: results of a 14-year single-center experience from Hungary

Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade’s experience from Lebanon

Gut-origin sepsis in the critically ill patient: pathophysiology and treatment

Diagnosis of nontuberculous mycobacterial disease in the era of surveillance chest CT scans

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials